ClinicalTrials.gg
Not yet recruitingNCT06904092Updated Jun 12, 2026

Efficacy and Mechanisms of TUS on Cognitive Deficits in Schizophrenia: Based on the Hippocampal-Prefrontal Circuit

An interventional study of Transcranial ultrasound stimulation in Cognitive Deficit in Schizophrenia, sponsored by Shanghai Mental Health Center. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Shanghai Mental Health Center · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Schizophrenia by Shanghai Mental Health Center — 15 open to participants now, 15 under way, none of them phase 3. Schizophrenia · Shanghai Mental Health Center.

Planned enrollment
14th of 50
140 · median 67
Started
2026
with 5 others
No phase
35 of 61
10 open now
Primary completion
2027-10
later than 7 of 14 live
Registered
53rd of 61
by date

Among the 61 studies in Schizophrenia by Shanghai Mental Health Center, this one is the 14th largest by planned enrollment of the 50 interventional ones that give a count, is one of 6 that started in 2026, is one of 35 with no phase, reaches primary completion later than 7 of the 14 other live ones, and was the 53rd registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

15 of the 61 studies in Schizophrenia by Shanghai Mental Health Center are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Schizophrenia by Shanghai Mental Health Center, or all of them as a file.
02

Study summary

Cognitive deficit is a core symptom of schizophrenia related to poorer functional outcome. Prior studies indicated that abnormalities in the hippocampus-prefrontal circuit and glutamate/GABA imbalances may lead to cognitive deficits. Based on the current background and our previous studies, it has been proved that TUS can modulate neural excitability and plasticity in the hippocampus. In this double-blind, randomized study, the efficacy of different treatment options and mechanisms of TUS on cognitive deficits will be investigated.

Read the detailed description

Cognitive deficit is a core symptom of schizophrenia related to poorer functional outcome which remains largely treatment refractory. Prior studies indicated that abnormalities in the hippocampus-prefrontal circuit and glutamate/GABA imbalances may be the root causes of cognitive deficits. Transcranial ultrasound stimulation (TUS), an emerging non-invasive neuromodulation technique with deep penetration ability, can modulate neural excitability and plasticity in the hippocampus. This is a 4-week double-blind randomized trial of TUS for cognitive deficits in schizophrenia, with either left hippocampus or left dorsolateral prefrontal cortex (DLPFC) or both targeted. This study aims to determine the efficacy of TUS and to reveal its underlying neural mechanism, especially with the hippocampus-prefrontal circuit, by means of TUS, as to assess cortical inhibition and excitability, EEG source imaging, and multi-model MRI. Neuropsychological assessments will also be conducted to develop the optimized treatment strategy. The study points to a novel and promising therapeutic neuromodulation approach that may improve the functional outcome of schizophrenia, which has been the main cause of mental disability.

03

Conditions studied

  • Cognitive Deficit in Schizophrenia

Keywords

  • Schizophrenia; Cognitive Deficit; Transcranial Ultrasound Stimulation; Hippocampus- Prefrontal Circuit
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet the diagnostic criteria for schizophrenia ;
  • Age18-50, right-handed, Han nationality;
  • Presence of cognitive deficit: defined as d' value \<0.5 in associative memory test;
  • Be in a stable condition, received second-generation antipsychotics for at least 4 weeks or more;
  • Written ;

Exclusion criteria

Exclusion Criteria:

  • Current or past neurological illness, severe physical diseases, substance abuse or alcohol dependence, mental retardation, pregnancy or lactation;
  • Uncooperative or risky patients with high excitement, stupor, disorder of words and deeds, negative suicide, etc.;
  • History of MECT or other physical therapy within 6 months;
  • History of epilepsy, or epileptic waves on the baseline EEG;
  • Ruled out share antiepileptic drugs (carbamazepine, valproic acid salt) or larger doses of benzodiazepine drugs (diazepam > 10mg/day, clonazepam > 2mg/day etc.), if necessary, remain unchanged during the course of treatment;
  • to TUS and MRI are present.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Active comparator
    single target group : left DLPFC

    35 eligible patients will be treated with active TUS on the left DLPFC and sham TUS on the left hippocampus for 4 weeks

    Device: Transcranial ultrasound stimulation

  • Active comparator
    single target group : left hippocampus

    35 eligible patients will be treated with active TUS on the left hippocampus and sham TUS on the left DLPFC for 4 weeks

    Device: Transcranial ultrasound stimulation

  • Active comparator
    both-target group : left DLPFC and left hippocampus

    35 eligible patients will be treated with active TUS for 4 weeks on the left DLPFC and left hippocampus

    Device: Transcranial ultrasound stimulation

  • Sham comparator
    sham TUS group

    35 eligible patients will be treated with sham TUS for 4 weeks on the left DLPFC and left hippocampus

    Device: Transcranial ultrasound stimulation

Interventions

  • DeviceTranscranial ultrasound stimulation

    The TUS was administered using Transcranial Ultrasound Stimulator UNS-III (model UNS-III), which has passed the safety test for medical electrical equipment (GB9706.1-2007). Transcranial ultrasound stimulation on the target. Duration:20 days (workdays for four consecutive weeks).

06

What researchers measure

Primary outcomes

  1. Change from baseline in associative memory test score

    Change from baseline in the associative memory test score at 4 weeks and 8 weeks.

    Time frame: baseline, 4 weeks and 8 weeks

Secondary outcomes

  1. Change of information processing speed and attention/vigilance

    Change from baseline in 4 MCCB subtests score at 4 weeks and 8 weeks.

    Time frame: baseline, 4 weeks and 8 weeks

  2. Change of working memory

    Change from baseline in N-back task at 4 weeks and 8 weeks. The outcome measures include accuracy, D-prime value, and reaction time.

    Time frame: baseline, 4 weeks and 8 weeks

  3. Change from baseline in Positive and Negative Syndrome Scale(PANSS)

    Change from baseline in Positive and Negative Syndrome Scale(PANSS) at 4 weeks and 8 weeks. The minimum to maximum value is 30-210. Lower scores mean a better outcome.

    Time frame: baseline, 4 weeks and 8 weeks

  4. Change of CGI score

    Change from baseline in Clinical Global Impression (CGI) at 4 weeks and 8 weeks.

    Time frame: baseline, 4 weeks and 8 weeks

  5. Change of Multi-modal Brain Neuroimaging in structure

    Brain structure data will be acquired.

    Time frame: baseline and 4 weeks

  6. Change of Multi-modal Brain Neuroimaging in resting- state fMRI

    Resting-state fMRI data will be acquired.

    Time frame: baseline and 4 weeks

  7. Change of Multi-modal Brain Neuroimaging in 1H-MRS

    1H-MRS data will be acquired.

    Time frame: baseline and 4 weeks

  8. Change of 64 channels EEG

    64 channels EEG data will be acquired.

    Time frame: baseline and 4 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Oct 2027, 15 months later.

Of 763 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 15 months is below that.

Counting every sponsor, half of 776 studies reached it within 32 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2025
First posted
Apr 1, 2025
StartEst.
Jul 1, 2026
Primary completionEst.
Oct 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06904092
Responsible party
Sponsor
First posted
Apr 1, 2025
Start date
Jul 1, 2026 (estimated)
Primary completion
Oct 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jun 12, 2026

Study contacts

Dengtang LIU
Contact
liudengtang@smhc.org.cn
021-34773434

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion